

B. at least one cell killing moiety that is adapted to kill specific cells bearing gonadotropin releasing hormone binding sites,

wherein the at least one cell targeting moiety consists essentially of gonadotropin releasing hormone and the at least one cell killing moiety consists essentially of a cell killing toxin;

wherein said chimeric toxins are adapted to bond to GnRh binding sites on adenocarcinoma cells, benign uterine lyomyoma cells, endometrial island cells and/or pituitary tumor adenoma cells; and

wherein said chemeric toxin is a linear protein consisting essentially of peptide bonds.

2. (Three times amended) Targeted fused chimeric toxins according to claim 1 wherein the specific cells bearing gonadotropin releasing hormone binding sites are [at least one member selected from the group consisting of] malignant adenocarcinoma cells[, benign uterine lyomyoma cells, endometrial island cells and pituitary tumor adenoma cells].

{Kindly add the following claim: }

29. (New) Targeted fused chimeric toxins comprising a genetically engineered molecule produced by fusing, at the level of cDNA:

A. at least one cell targeting moiety encoding GnRH or a GnRH analog that starts with Meth and that is adapted to recognize specific cells bearing gonadotropin releasing hormone binding sites; and

B. at least one cell killing moiety that is adapted to kill specific cells bearing gonadotropin releasing hormone binding sites,

wherein the at least one cell targeting moiety consists essentially of gonadotropin releasing hormone and the at least one cell killing moiety consists essentially of a cell killing toxin; and